GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT03374956

CompletedPhase 3Results posted

Individualized Obesity Pharmacotherapy

Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial

Lead sponsor

Mayo Clinic

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

193

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03374956

Org study ID17-003449

Timeline

Milestones

Study start2017-12-11actual

Study first posted2017-12-15actual

Primary completion2022-05-26actual

Study completion2022-05-26actual

Last update posted2023-07-18actual

Results first posted2023-07-18actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Adults with obesity (BMI >30 Kg/m2); these will be otherwise healthy individuals with no unstable psychiatric disease and controlled comorbidities or other diseases.

•Gender: Men or women. Women of childbearing potential will have negative pregnancy tests within 48 hours of enrollment and before each radiation exposure.

Exclusion criteria

•Abdominal bariatric surgery

•Positive history of chronic gastrointestinal diseases, or systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., orlistat, within the last 6 months.

•Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia). If such a dysfunction is identified by an anxiety or depression score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.

•Hypersensitivity to any of the study medications.

•No contraindications to all FDA-approved medications

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

6 endpoints

Primary/registry result

Change in Total Body Weight

Time frame:baseline to 12 weeks

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (median), percent change	95% CI
Intervention Group	-7.7	-11 – -4.7
Control Group	-6.5	-11 – -2.3

Primary/protocol endpoint

Change in Total Body Weight

Time frame:baseline to 12 weeks

Body weight, % change

percent change from baseline, improvement

Secondary/registry result

Percentage of Responders

Time frame:baseline to 12 weeks

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Intervention Group	81	—
Control Group	80	—

Secondary/registry result

Percentage of Responders

Time frame:baseline to 12 weeks

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Intervention Group	44	—
Control Group	40	—

Secondary/protocol endpoint

Percentage of Responders

Time frame:baseline to 12 weeks

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Responders

Time frame:baseline to 12 weeks

≥10% weight-loss responders

threshold achievement, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic.
Obesity (Silver Spring, Md.)2021 Apr (month)PMID33759389doi:10.1002/oby.23120via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.